Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 16443


A Case of a Malignant Cutaneous Mixed Tumor (Chondroid Syringoma) of the Scapula Treated With Staged Margin-Controlled Excision.

Lal K, Morrell TJ, Cunningham M, OʼDonnell P, Levin NA, Cornejo KM.

Am J Dermatopathol. 2018 Mar 6. doi: 10.1097/DAD.0000000000001131. [Epub ahead of print]


Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?

Sivaraman A, Benfante N, Touijer K, Coleman J, Scardino P, Laudone V, Eastham J.

Investig Clin Urol. 2018 Mar;59(2):83-90. doi: 10.4111/icu.2018.59.2.83. Epub 2018 Feb 22.


Predictors for the detection of prostate cancer and clinically significant prostate cancer using TRUS-guided biopsy in patients with negative initial biopsy results.

Yoo S, Park J, Cho SY, Cho MC, Ku JH, Son H, Kwak C, Kim HH, Jeong H.

World J Urol. 2018 Mar 1. doi: 10.1007/s00345-018-2239-1. [Epub ahead of print]


Synthesis and Binding of a Novel PSMA-specific Conjugate.

Holmberg AR, Marquez M, Lennartsson L, Meurling L, Nilsson S.

Anticancer Res. 2018 Mar;38(3):1531-1537.


A Panel of Biomarkers for Diagnosis of Prostate Cancer Using Urine Samples.

Guo J, Yang J, Zhang X, Feng X, Zhang H, Chen L, Johnson H, Persson JL, Xiao K.

Anticancer Res. 2018 Mar;38(3):1471-1477.


A comparison of operative and margin outcomes from surgeon learning curves in robot assisted radical prostatectomy in a changing referral practice.

Jaulim A, Srinivasan A, Hori S, Kumar N, Warren AY, Shah NC, Gnanapragasam VJ.

Ann R Coll Surg Engl. 2018 Mar;100(3):226-229. doi: 10.1308/rcsann.2018.0001. Epub 2018 Feb 27.


Transition zone and anterior stromal prostate cancers: Evaluation of discriminant location criteria using multiparametric fusion-guided biopsy.

Tavolaro S, Mozer P, Roupret M, Comperat E, Rozet F, Barret E, Drouin S, Vaessen C, Lucidarme O, Cussenot O, Boudghène F, Renard-Penna R.

Diagn Interv Imaging. 2018 Feb 21. pii: S2211-5684(18)30008-1. doi: 10.1016/j.diii.2018.01.006. [Epub ahead of print]


Prostate cancer treated with reduced-volume intensity-modulated radiation therapy: Report on the 5-year outcome of a prospective series.

Luo HC, Fu ZC, Cheng HH, Lei Y, Liao SG, Feng J, Yin Q, Chen QH, Lin GS, Zhu JF, Xu JF, Dian W.

Medicine (Baltimore). 2017 Dec;96(52):e9450. doi: 10.1097/MD.0000000000009450.


Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis.

Vickers A, Vertosick EA, Sjoberg DD, Hamdy F, Neal D, Bjartell A, Hugosson J, Donovan JL, Villers A, Zappala S, Lilja H.

J Urol. 2018 Jan 31. pii: S0022-5347(18)30107-1. doi: 10.1016/j.juro.2018.01.070. [Epub ahead of print]


The Within-Group Discrimination Ability of the Cancer of the Prostate Risk Assessment Score for Men with Intermediate-Risk Prostate Cancer.

Kang HW, Jung HD, Lee JY, Kwon JK, Jeh SU, Cho KS, Ham WS, Choi YD.

J Korean Med Sci. 2018 Jan 29;33(5):e36. doi: 10.3346/jkms.2018.33.e36.


Does [-2]Pro-Prostate Specific Antigen Meet the Criteria to Justify Its Inclusion in the Clinical Decision-Making Process?

Sanchis-Bonet A, Barrionuevo-González M, Bajo-Chueca A, Morales-Palacios N, Sanchez-Chapado M.

Urol Int. 2018;100(2):146-154. doi: 10.1159/000481439. Epub 2018 Jan 18.


Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.

Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Garcia SB, Muir K, Grönberg H, Wiklund F, Aly M, Schleutker J, Sipeky C, Tammela TL, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Cuk K, Saum KU, Park JY, Sellers TA, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Karow DS, Mills IG, Andreassen OA, Dale AM; PRACTICAL Consortium*.

BMJ. 2018 Jan 10;360:j5757. doi: 10.1136/bmj.j5757.


Image-guided, whole-pelvic, intensity-modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients.

Byun SJ, Kim YS, Ahn H, Kim CS.

PLoS One. 2018 Jan 10;13(1):e0190479. doi: 10.1371/journal.pone.0190479. eCollection 2018.


Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.

Murata Y, Tatsugami K, Yoshikawa M, Hamaguchi M, Yamada S, Hayakawa Y, Ueda K, Momosaki S, Sakamoto N.

Int J Urol. 2018 Jan 8. doi: 10.1111/iju.13514. [Epub ahead of print]


Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?

Nguyen DP, Vertosick EA, Sharma V, Corradi RB, Vilaseca A, Takeda T, Sjoberg DD, Benfante N, Fine SW, Reuter VE, Scardino PT, Eastham JA, Karnes RJ, Touijer KA.

J Urol. 2018 Jan 4. pii: S0022-5347(18)30005-3. doi: 10.1016/j.juro.2017.12.056. [Epub ahead of print]


NCCN Favorable Intermediate Risk Prostate Cancer: Is Active Surveillance Appropriate?

Aghazadeh MA, Frankel J, Belanger M, McLaughlin T, Tortora J, Staff I, Wagner JR.

J Urol. 2017 Dec 26. pii: S0022-5347(17)78182-7. doi: 10.1016/j.juro.2017.12.049. [Epub ahead of print]


Is There a Role for Functional MRI for the Assessment of Extracapsular Extension in Prostate Cancer?

Sertdemir M, Weidner AM, Schoenberg SO, Morelli JN, Haecker A, Kirchner M, Weiss C, Hausmann D, Dinter DJ, Attenberger UI.

Anticancer Res. 2018 Jan;38(1):427-432.


Long-term Outcomes of a Dose-reduction Trial to Decrease Late Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy.

Sasaki N, Yamazaki H, Shimizu D, Suzuki G, Masui K, Nakamura S, Okabe H, Nishikawa T, Yoshida K.

Anticancer Res. 2018 Jan;38(1):385-391.


T2E (TMPRSS2-ERG) fusion transcripts are associated with higher levels of AMACR mRNA and a subsequent prostate cancer diagnosis in patients with atypical small acinar proliferation.

Eryilmaz IE, Kordan Y, Vuruskan BA, Kaygısız O, Tunca B, Cecener G.

Gene. 2018 Mar 1;645:69-75. doi: 10.1016/j.gene.2017.12.038. Epub 2017 Dec 22.


Prediction of organ-confined disease after robot-assisted radical prostatectomy in patients with clinically locally-advanced prostate cancer.

Kang HW, Jung HD, Lee JY, Kwon JK, Jeh SU, Cho KS, Ham WS, Choi YD.

Asian J Surg. 2017 Dec 20. pii: S1015-9584(17)30440-2. doi: 10.1016/j.asjsur.2017.10.005. [Epub ahead of print]

Supplemental Content

Loading ...
Support Center